XOMA Corporation (NASDAQ: XOMA), announced today it has acquired a royalty interest in six clinical-stage assets targeting the adenosine pathway for $10.0 million from Palobiofarma S.L.One of the assets, NIR178, is being developed by Novartis as a novel checkpoint inhibitor for the treatment of solid tumors.Five of the assets are being developed by Palobiofarma.

“We are impressed by Palobiofarma’s expertise in adenosine receptor biology and what they have achieved.It’s unusual today to discover a private company that has three distinct compounds in Phase 2 development and three additional compounds in Phase 1 clinical studies. We are particularly attracted to NIR178, which is being developed by Novartis as a potential novel immuno-oncology agent for the treatment of multiple solid tumors,” said Jim Neal, Chief Executive Officer at XOMA.“Palobiofarma’s portfolio covers all four adenosine receptor sub-types.Among these sub-types, A2AR receptor antagonists are an emerging class of “next-generation” immune checkpoint agents in oncology. In addition, early data suggests adenosine receptor antagonists have potential in indications beyond oncology, including psoriasis and NASH.”

Inveready, the lead investor in the Seed Stage in Palobiofarma, has invested an additional $2.0 million through their specialized venture fund, Inveready Biotech III, for the development of all six clinical – stage assets. “The investment in Palobiofarma is a clear example of how a Spanish biotechnology company is capable of advancing therapies for global markets. It is a privilege for us to be able to continue to support them in this next phase of development” says Roger Pique, General Partner at Inveready.

Subscribe to Directory
Write an Article

Recent News

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Un estudio de INCLIVA muestra el efecto ...

by INCLIVA

Han desarrollado un estudio para evaluar la correlación entre el teji...

Photos Stream